Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.
Financial Results:
Concord Biotech Ltd reported Revenues for Q4FY25 of ₹430.00 Crores up from ₹319.00 Crore year on year, a rise of 34.8%.
Total Expenses for Q4FY25 of ₹256.00 Crores up from ₹201.00 Crores year on year, a rise of 27.36%.
Consolidated Net Profit of ₹140.00 Crores up 47.37% from ₹95.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹13.42, up 47.80% from ₹9.08 in the same quarter of the previous year.